Sellas Life Sciences Receives Fast Track Designation From FDA For SLS009 For Treatment Of Relapsed/Refractory Peripheral T-cell Lymphomas
Portfolio Pulse from Benzinga Newsdesk
Sellas Life Sciences has received Fast Track Designation from the FDA for SLS009, a treatment for relapsed/refractory Peripheral T-cell Lymphomas (PTCL). The drug demonstrated a 36.4% clinical response in a Phase 1 study, compared to the standard of care's 25.8% response rate. This designation accelerates SLS009's path to FDA submission for treatment of PTCL.
October 30, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sellas Life Sciences' SLS009 has received Fast Track Designation from the FDA, potentially accelerating its path to market. This could positively impact the company's stock in the short term.
Fast Track Designation from the FDA is a significant regulatory milestone that can accelerate the development and review of a drug. This news is highly relevant to Sellas Life Sciences as it directly pertains to one of their products, SLS009. The potential for accelerated market entry could increase investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100